Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

Ralphbeach Sep. 9 at 1:07 PM

$CUE is a sleeper. Merck launches 3 billion dollar plan to reinvest of Keytruda patent expiry in 2028. Cue-101 working Keytruda. Impressive backgrounds on leadership and advisory board: Roche Pharma, Pfizer, Johnson & Johnson, Janssen, Bayer, Scripps. Read their bios, very impressive.

0 · Reply

ibaian Sep. 4 at 10:30 PM

$CUE Tomorrow 🚀

0 · Reply

ibaian Sep. 4 at 10:29 PM

$CUE

0 · Reply

Ralphbeach Aug. 27 at 7:41 PM

$IXHL so many other stocks to invest in. This Australia dog has too many fleas. Too many hurdles...all the phases. All the cash needed. The pumpers on all the different social media. Too much competition with companies that have a stronger balance sheet. Look at $ACHV $CUE $LCTX $CLYM

3 · Reply

Ralphbeach Aug. 27 at 2:23 PM

$IXHL make your swap to $CUE They will be at the Cantor global Healthcare conference. Lucid capital is bullish.

0 · Reply

DARKP00L Aug. 25 at 5:29 PM

$CUE 13:27 on Aug. 25 2025 LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4 #tradeideas

0 · Reply

JarvisFlow Aug. 25 at 5:28 PM

LUCID CAPITAL MARKETS updates rating for Cue Biopharma ( $CUE ) to Buy, target set at 4.

0 · Reply

ObsidianSecurities Aug. 23 at 10:33 AM

$CUE Cue Health Inc is facing post-pandemic demand collapse for COVID tests and cash burn concerns

0 · Reply

Doozio Aug. 22 at 1:09 PM

Well they didn’t then bahhhht they are now as the huckleberries are arriving for XBI IWM n KWEB as Roger shud start rocking on $CUE 🐒🍌🧠⏰♾️

0 · Reply

Ralphbeach Aug. 22 at 12:33 AM

$CUE tee it up...

1 · Reply

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 27 days ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 7 weeks ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 2 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 2 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 4 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 4 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 4 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 5 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 5 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 5 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:05 PM EDT - 5 months ago

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:02 PM EDT - 5 months ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 5 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 10 months ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 10 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 10 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 10 months ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 10 months ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 1 year ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Feb 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Ralphbeach Sep. 9 at 1:07 PM

0 · Reply

ibaian Sep. 4 at 10:30 PM

$CUE Tomorrow 🚀

0 · Reply

ibaian Sep. 4 at 10:29 PM

$CUE

0 · Reply

Ralphbeach Aug. 27 at 7:41 PM

3 · Reply

Ralphbeach Aug. 27 at 2:23 PM

$IXHL make your swap to $CUE They will be at the Cantor global Healthcare conference. Lucid capital is bullish.

0 · Reply

DARKP00L Aug. 25 at 5:29 PM

$CUE 13:27 on Aug. 25 2025 LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4 #tradeideas

0 · Reply

JarvisFlow Aug. 25 at 5:28 PM

LUCID CAPITAL MARKETS updates rating for Cue Biopharma ( $CUE ) to Buy, target set at 4.

0 · Reply

ObsidianSecurities Aug. 23 at 10:33 AM

$CUE Cue Health Inc is facing post-pandemic demand collapse for COVID tests and cash burn concerns

0 · Reply

Doozio Aug. 22 at 1:09 PM

Well they didn’t then bahhhht they are now as the huckleberries are arriving for XBI IWM n KWEB as Roger shud start rocking on $CUE 🐒🍌🧠⏰♾️

0 · Reply

Ralphbeach Aug. 22 at 12:33 AM

$CUE tee it up...

1 · Reply

tyrus6 Aug. 20 at 4:02 AM

$ICU -- BioCryst Pharmaceuticals (NASDAQ: $BCRX) What happened: After its CFO announced a resignation effective Apr 9, 2025, the board appointed CEO Jon Stonehouse as interim CFO and interim principal accounting officer on Apr 7, effective Apr 9. Stock reaction: Around the announcement window, Apr 8 close was $6.47 vs ~$6.50 on Apr 7 (≈ –0.5% 1-day), i.e., little immediate move. May 5 (intraday high) $11.11 June 4 (intraday high) $11.31 Aug. 19 closing price: $8.28 -- Cue Biopharma (NASDAQ: $CUE) What happened: On Jun 13, 2025, the company disclosed CEO Dan Passeri would serve as interim principal financial officer while it searched for a new CFO. Stock reaction: Jun 13 close $0.60 vs $0.64 on Jun 12 (≈ –6.3% 1-day). July 16th (midday high) share price: $1.03 Aug. 19th share closing price: $0.81

0 · Reply

d_risk Aug. 13 at 5:34 AM

$CUE - Cue Biopharma, Inc. - 10Q - Updated Risk Factors No substantial changes in risk factor headings; CUE highlights ongoing going concern doubts, expanded U.S. trade policy and tariff risks, new tax law impacts, and Nasdaq listing compliance challenges with potential delisting. #Biopharma #NasdaqCompliance #TariffRisks #TradePolicy #GoingConcern 🟢 Added 🟠 Removed https://d-risk.ai/CUE/10-Q/2025-08-12

0 · Reply

CatCapital_ai Aug. 12 at 8:07 PM

$CUE Earnings - Q2/2025 Revenue: $2.95M ✅ vs. $2.4M est. EPS: $(0.09) ✅ vs. $(0.14) est. Cue Biopharma advances IND plans for CUE-401 after FDA feedback, reports promising Phase 1b data for CUE-101 in HPV+ head and neck cancer, and collaborates with Boehringer Ingelheim on CUE-501. Raised $20M in Q2 to support ongoing autoimmune and cancer programs.

0 · Reply

ES33 Aug. 10 at 2:14 AM

$CUE it looks like the stock’s closing price has been below $1 since late March. Shouldn’t they have gotten a deficiency notice from Nasdaq? I understand that if they get a notice they have 6 months to regain compliance plus an option for another 6 months extension?

0 · Reply

NVDAMillionaire Jul. 30 at 1:08 AM

$CUE Great piece that accurately captures CUE's current position. So if you want to refresh your understanding of CUE or learn about CUE for the first time, this is essential reading. https://beyondspx.com/article/cue-biopharma-precision-immunotherapy-platform-pivots-towards-partnerships-amidst-financial-headwinds-nasdaq-cue

1 · Reply

Ralphbeach Jul. 26 at 12:37 AM

$CUE Cue Biopharma, in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and support from LG Chem, Ltd., Seoul, South Korea. Is the Alligator in the sewer still trolling?

0 · Reply

stockinfocuz_ Jul. 24 at 6:11 PM

$ONCY), Cue Biopharma, Inc. (NASDAQ: $CUE), Verastem, Inc. (NASDAQ: $VSTM), Allogene Therapeutics, Inc. (NASDAQ: $ALLO), and Perspective Therapeutics, Inc. (NYSE-American: $CATX).

0 · Reply

inno56 Jul. 22 at 10:49 PM

$CUE @LouBasenese Any comments regarding the news from last week? Is this one finally turning the corner?

0 · Reply

Smittysixty Jul. 21 at 4:11 PM

When you see $PPBT thrown into lists alongside $ALXO $JANX $CUE $HOWL, that’s not analysis—it’s camouflage. It’s a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data. 💥 Purple Biotech stands alone: • Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients. • CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation. • Cash runway to 2026, focused pipeline, expanding IP, and a strategy that’s quietly creating asymmetrical upside. These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets. Don’t let ticker bundling blur the signal. This biotech isn’t rising with the tide—it’s cutting through it. 🧬👊

1 · Reply

ThisWi11hurt Jul. 21 at 1:46 PM

$PPBT keeping it real I don’t get too into the nitty gritty of the methods of action etc. but Grok tells me PPBT is in the same class as $ALXO $JANX $CUE $HOWL. All of these stocks, PPBT included are drifting up ready for breakouts. Cancer funding announcements are about to come out I can feel it

1 · Reply

Invest2live Jul. 20 at 9:42 PM

$CUE 43% already; congrats 🎈👏🎊🌿 Checkout $ASRT

0 · Reply

Sanvangonza1 Jul. 18 at 5:22 PM

$WGRX $CUE looking primed 👀

0 · Reply

Market Cap	59.71M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.14

Volume	75,500
Avg Vol	293,418
Day's Range	N/A - N/A
Shares Out	76.85M
Stochastic %K	8%
Beta	1.58
Analysts	Strong Sell
Price Target	$4.00